Table 2 Association of miR-339-5p expression with clinicopathological data from breast cancer patients
Variable | n | MiR-339-5p expression, n(%) | Pvalue |
|---|---|---|---|
Age (years) | Â | Â | Â |
   ≤35 | 6 | 0 (0) | 0.12 |
   35-55 | 48 | 18 (37.5) |  |
   > 55 | 36 | 9 (25.0) |  |
Tumor size (cm) | Â | Â | Â |
   ≤2 | 4 | 2 (50.0) | 0.67 |
   2-5 | 68 | 20 (29.4) |  |
   > 5 | 18 | 5 (27.8) |  |
Lymph node metastases | Â | Â | Â |
   0 | 29 | 14 (48.3) | 0.018 |
   1-3 | 33 | 9 (27.3) |  |
   > 3 | 28 | 4 (14.3) |  |
Grade | Â | Â | Â |
   I | 4 | 1 (25.0) | 0.17 |
   II | 57 | 21 (36.8) |  |
   III | 29 | 5 (17.2) |  |
Stage | Â | Â | 0.005 |
   I - II | 50 | 21 (42.0) |  |
   III - IV | 40 | 6 (15.0) |  |
Estrogen receptor | Â | Â | Â |
   - | 57 | 18 (36.1) | 0.67 |
   + | 33 | 9 (27.3) |  |
Progesterone receptor | Â | Â | Â |
   - | 56 | 16 (28.6) | 0.70 |
   + | 34 | 11 (32.4) |  |
c-erbB-2 expression | Â | Â | Â |
   Low | 59 | 18 (30.5) | 0.89 |
   High | 31 | 9 (29.0) |  |